A large cohort study examining more than 125,000 adults in the U.S. found that the majority of patients discontinue GLP-1 RA therapy within the first year, with those without Type 2 diabetes showing the highest dropout rates.
Here are five more notes:
- The study, published Jan. 31 in JAMA Network Open, found that 64.8% of patients without Type 2 diabetes discontinued GLP-1 RAs within the first year compared to 46.5% of those with diabetes.
- A 1% reduction in weight lowered the likelihood of discontinuation by more than 3%, showing the importance of weight loss in maintaining treatment adherence.
- Gastrointestinal issues such as nausea or vomiting significantly increased discontinuation rates, particularly among patients with Type 2 diabetes. Also, higher income was linked to lower discontinuation rates especially among those with Type 2 diabetes.
- Patients who received prescriptions from specialists, including endocrinologists or obesity medicine experts, were more likely to continue treatment compared to those who were prescribed by primary care providers.
- The new research comes after a Blue Cross Blue Shield Association study in May showed that 30% of patients stopped using GLP-1 medications such as Wegovy and Saxenda within the first month, and 58% of patients discontinue GLP-1 use before reaching a clinically meaningful health benefit.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
